Lumida
/MMSI
⌘K
Merit Medical Systems Inc

Merit Medical Systems Inc

MMSI
$86.36USD-0.13%-0.11 today

MARKET CAP

5.2B

P/E (TTM)

21.1x

FWD P/E

19.4x

DAY RANGE

$85 – $88

52W RANGE

$60
$95

AI Summary

Stalk
StalkMedium

The stock has mounted a strong recovery off its mid-May lows, clearing the 200-day SMA and establishing a bullish EMA stack. After a steep rally into the 52-week high area, price is consolidating above the 20 EMA, creating a structurally favorable zone for pullback entries. Medium-term, the Stage 2 uptrend remains intact above rising EMAs, but near-term overbought signals and overhead resistance counsel patience until support around the 20 EMA is tested and absorbed.

  • Q2 revenue $418.8 M (up 10% YoY) topped estimates
  • Non-GAAP operating margin expanded to 22.6% on tighter cost controls
  • Profitability factors are weak, reflecting low earnings yield pressures
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.1B$1.2B$1.3B$1.4B$1.5B
YoY %+11.5%+7.1%+9.2%+7.9%+11.8%
P / Sales3.3x3.5x3.5x4.2x3.5x
EV / Sales3.8x3.9x4.0x4.7x3.9x
Gross Profit, Adj.$485.3M$519.1M$583.9M$643.3M$738.3M
YoY %+21.0%+7.0%+12.5%+10.2%+14.8%
Margin %45.2%45.1%46.4%47.4%48.7%
EV / Gross Profit8.5x8.6x8.6x10.0x8.1x
EBITDA, Adj.$174.2M$178.3M$215.7M$258.4M$307.9M
YoY %+14.0%+2.3%+21.0%+19.8%+19.2%
Margin %16.2%15.5%17.2%19.0%20.3%
EV / EBITDA23.6x25.1x23.1x24.8x19.4x
EBIT$60.9M$87.6M$123.9M$155.7M$184.7M
YoY %+3999.9%+43.7%+41.5%+25.6%+18.6%
Margin %5.7%7.6%9.9%11.5%12.2%
EV / EBIT67.5x51.1x40.3x41.1x32.4x
Net Income$48.5M$74.5M$94.4M$120.4M$128.5M
YoY %+592.3%+53.8%+26.7%+27.5%+6.8%
Net Margin4.5%6.5%7.5%8.9%8.5%
EPS (GAAP)$0.84$1.29$1.62$2.03$2.13
YoY %+566.7%+53.6%+25.6%+25.3%+4.9%